Graves

By Targets:	Bacterial (1) Drug Derivative (1) Endogenous Metabolite (1) Environmental Pollutants (1) Free Fatty Acid Receptor (1) IGF-1R (1) PKA (1) Reference Standards (1) Thyroid Hormone Receptor (3) TNF Receptor (1) TSH Receptor (6)
By Research Areas:	Cancer (1) Endocrinology (7) Infection (1) Inflammation/Immunology (3) Metabolic Disease (4)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0346

Propylthiouracil 3 Publications Verification 6-n-Propylthiouracil; 6-Propyl-2-thiouracil; PTU	Environmental Pollutants Thyroid Hormone Receptor	Endocrinology
Propylthiouracil (6-n-Propylthiouracil), a thioamide antithyroid agent, is an orally active thyroperoxidase and type-1 deiodinase (DIO1) inhibitor. Propylthiouracil can be used for the Graves disease and hyperthyroidism research .

HY-P991202

Anti-TSHR Antibody (M22)	TSH Receptor PKA	Metabolic Disease Inflammation/Immunology
Anti-TSHR Antibody (M22) is a selective agonist targeting TSHR (thyroid-stimulating hormone receptor), acting through competitive binding to the extracellular domain of TSHR. Anti-TSHR Antibody (M22) can mimic the biological effects of thyroid-stimulating hormone (TSH), activating downstream cAMP-PKA and other signaling pathways. Anti-TSHR Antibody (M22) can stimulate the proliferation of thyroid follicular epithelial cells and human umbilical vein endothelial cells (HUVECs), promote angiogenesis and tube formation, cell migration, and also upregulate the expression of angiogenesis-related proteins such as PROX1. Anti-TSHR Antibody (M22) can be used in research areas such as the mechanisms of goiter formation in Graves' disease (GD), angiogenesis regulation, and TSHR antagonist screening .

HY-12381

ML224 1 Publications Verification NCGC00242364; ANTAG3	TSH Receptor	Endocrinology
ML224 (NCGC00242364) is a selective TSHR antagonist with an IC₅₀ value of 2.1 µM. ML224 can be used in the study of Graves' disease and other thyroid disorders.

HY-P99670

Iscalimab CFZ-533; OM11-62MF	TNF Receptor	Metabolic Disease Inflammation/Immunology
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (K_D: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases .

HY-114610

13Z,16Z-Docosadienoic acid	Endogenous Metabolite Free Fatty Acid Receptor Bacterial	Infection Cancer
13Z,16Z-Docosadienoic acid is a GPR120 agonist with bactericidal activity. 13Z,16Z-Docosadienoic acid serves as a potential biomarker for canine mammary tumors. 13Z,16Z-Docosadienoic acid is used in the research of bacterial infections, Lyme disease, Graves' disease and mammary tumors .

HY-129995A

TSHR antagonist S37a	TSH Receptor	Endocrinology
TSHR antagonist S37a is a highly selective thyrotropin receptor (TSHR) antagonist, with potential for the treatment of Graves' orbitopathy .

HY-153213

Org 274179-0	TSH Receptor	Metabolic Disease
Org 274179-0 is a potent and allosteric antagonist of thyroid-stimulating hormone (TSH) receptor, with an IC₅₀ of nanomolar concentration. Org 274179-0 completely inhibits TSH (and TSI)-mediated TSH receptor activation with little effect on the potency of TSH. Org 274179-0 can be used for the research of Graves' disease (GD) .

HY-18286

NCGC00229600	TSH Receptor	Endocrinology
NCGC00229600 is an allosteric inverse agonist of thyrotropin receptor (TSHR). NCGC00229600 inhibits both TSH and stimulating antibody activation of TSHRs endogenously expressed in Graves' disease .

HY-N10348

Progoitrin	Others Drug Derivative	Endocrinology
Progoitrin is a sulfur-containing glucosinolate, as well as a naturally occurring orally active thioglycoside. Progoitrin acts as a hepatotoxin and antithyroid agent. Progoitrin is quantitatively converted to goitrin in vivo, including via a gastrointestinal hydrolysis pathway that does not require exogenous myrosinase, thereby blocking the organification of iodine in the thyroid gland and inhibiting the uptake and accumulation of radioactive iodine. Progoitrin can be used in studies related to Graves' disease .

HY-153213A

Org 274178-0	TSH Receptor	Endocrinology
Org 274178-0 is a selective thyroid-stimulating hormone receptor (TSHR) antagonist with a pIC₅₀ value for TSHR is 5.03. Org 274178-0 inhibits the activation of cAMP signaling pathway and phospholipase C (PLC) signaling pathway mediated by thyroid-stimulating hormone (TSH) and TSH receptor-stimulating immunoglobulins (TSIs). Org 274178-0 is promising for research of Graves’ disease and Graves’ ophthalmopathy .

HY-127024A

TR antagonist 2	Thyroid Hormone Receptor	Metabolic Disease
TR antagonist 2 (Compound 10a) is a competitive thyroid hormone receptors (TRα/β) antagonist (IC₅₀=47 nM). TR antagonist 2 competes with triiodothyronine (T₃) for binding to the ligand-binding domain of TR to block receptor-coactivator complex formation and inhibit target gene transcription, reducing thyroid hormone-mediated hypermetabolic effects. TR antagonist 2 is promising for research of hyperthyroidism (e.g., Graves' disease) and thyrotoxicosis .

HY-P991255

VRDN-002	IGF-1R	Inflammation/Immunology
VRDN-002 is a human monoclonal antibody (mAb) targeting IGF1R/CD221. VRDN-002 reduces inflammation and proptosis in thyroid eye disease (TED). VPI-2690B can be used in Graves ophthalmopathy research .

HY-B0346R

Propylthiouracil (Standard) 6-n-Propylthiouracil (Standard); 6-Propyl-2-thiouracil (Standard); PTU (Standard)	Thyroid Hormone Receptor Reference Standards	Endocrinology
Propylthiouracil (Standard) is the analytical standard of Propylthiouracil. This product is intended for research and analytical applications. Propylthiouracil (6-n-Propylthiouracil), a thioamide antithyroid agent, is an orally active thyroperoxidase and type-1 deiodinase (DIO1) inhibitor. Propylthiouracil can be used for the Graves disease and hyperthyroidism research .

Cat. No.	Product Name

HY-L131

Osteogenesis Compound Library	886 compounds
Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health. Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc. MCE offers a unique collection of 886 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.

Osteogenesis Compound Library

886 compounds

Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health.

Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc.

MCE offers a unique collection of 886 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.

HY-L003

Apoptosis Compound Library	3,407 compounds
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease. MCE designs a unique collection of 3,407 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

Apoptosis Compound Library

3,407 compounds

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease.

MCE designs a unique collection of 3,407 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

Cat. No.	Product Name	Target	Research Area	Image

HY-P991202

Anti-TSHR Antibody (M22)	TSH Receptor PKA	Metabolic Disease Inflammation/Immunology
Anti-TSHR Antibody (M22) is a selective agonist targeting TSHR (thyroid-stimulating hormone receptor), acting through competitive binding to the extracellular domain of TSHR. Anti-TSHR Antibody (M22) can mimic the biological effects of thyroid-stimulating hormone (TSH), activating downstream cAMP-PKA and other signaling pathways. Anti-TSHR Antibody (M22) can stimulate the proliferation of thyroid follicular epithelial cells and human umbilical vein endothelial cells (HUVECs), promote angiogenesis and tube formation, cell migration, and also upregulate the expression of angiogenesis-related proteins such as PROX1. Anti-TSHR Antibody (M22) can be used in research areas such as the mechanisms of goiter formation in Graves' disease (GD), angiogenesis regulation, and TSHR antagonist screening .

HY-P99670

Iscalimab CFZ-533; OM11-62MF	TNF Receptor	Metabolic Disease Inflammation/Immunology
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (K_D: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases .

HY-P991255

VRDN-002	IGF-1R	Inflammation/Immunology
VRDN-002 is a human monoclonal antibody (mAb) targeting IGF1R/CD221. VRDN-002 reduces inflammation and proptosis in thyroid eye disease (TED). VPI-2690B can be used in Graves ophthalmopathy research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-114610

13Z,16Z-Docosadienoic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Free Fatty Acid Receptor Bacterial
13Z,16Z-Docosadienoic acid is a GPR120 agonist with bactericidal activity. 13Z,16Z-Docosadienoic acid serves as a potential biomarker for canine mammary tumors. 13Z,16Z-Docosadienoic acid is used in the research of bacterial infections, Lyme disease, Graves' disease and mammary tumors .

HY-N10348

Progoitrin	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Glucosinolates Plants Brassica napus var. napobrassica (L.) Rchb. Brassicaceae Disease Research Fields Endocrinology Source Classification	Others Drug Derivative
Progoitrin is a sulfur-containing glucosinolate, as well as a naturally occurring orally active thioglycoside. Progoitrin acts as a hepatotoxin and antithyroid agent. Progoitrin is quantitatively converted to goitrin in vivo, including via a gastrointestinal hydrolysis pathway that does not require exogenous myrosinase, thereby blocking the organification of iodine in the thyroid gland and inhibiting the uptake and accumulation of radioactive iodine. Progoitrin can be used in studies related to Graves' disease .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products